Nektar Therapeutics (NKTR) Misses Q2 EPS by 2c

Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.39), $0.02 worse than the analyst estimate of ($0.37). Revenue for the quarter came in at $34.6 million versus the consensus estimate of $34.23 million.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• XP Inc. (XP) Tops Q2 EPS by 8c